Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse.
暂无分享,去创建一个
J. Friedberg | L. Constine | J. Liesveld | M. Becker | Jonathan W Friedberg | Jane L Liesveld | C. Casulo | Louis S Constine | Michael W Becker | S. Dhakal | Sughosh Dhakal | James E Bates | Carla Casulo | J. Bates | Sughosh Dhakal
[1] J. Rowe,et al. Strikingly high false positivity of surveillance FDG‐PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era , 2013, American journal of hematology.
[2] A. Wirth. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era , 2007, Leukemia & lymphoma.
[3] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Rübe,et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Advani,et al. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. , 2015, International journal of radiation oncology, biology, physics.
[6] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[7] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[8] Chunhong Hu,et al. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis , 2015, Acta Haematologica.
[9] J. Friedberg,et al. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. , 2010, International journal of radiation oncology, biology, physics.
[10] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Mareschal,et al. PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[12] G. Ceresoli,et al. Consolidation Radiotherapy to Bulky or Semibulky Lesions in the Management of Stage III–IV Diffuse Large B Cell Lymphomas , 2000, Oncology.
[13] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[14] C. Flowers,et al. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[15] L. Gordon,et al. Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project , 2015, Cancer.
[16] D. Heo,et al. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. , 2015, International journal of radiation oncology, biology, physics.
[17] J. Friedberg,et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. , 2013, The New England journal of medicine.
[18] R. Coleman,et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. , 2012, International journal of radiation oncology, biology, physics.
[19] Christine F. Wogan,et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Molina,et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Staudt,et al. Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.
[22] S. Tucker,et al. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. , 2000, International journal of radiation oncology, biology, physics.
[23] C. Flowers,et al. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. , 2013, International journal of radiation oncology, biology, physics.
[24] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[25] J. Earle,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Friedberg,et al. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. , 2009, International journal of radiation oncology, biology, physics.
[27] Junshik Hong,et al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma , 2014, Leukemia & lymphoma.
[28] B. Hill,et al. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients , 2015, Leukemia & lymphoma.
[29] S. Beriwal,et al. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Cerhan,et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[33] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[34] S. Sacchi,et al. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma , 2011, Leukemia & lymphoma.
[35] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] B. Kavanagh,et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. , 2008, International journal of radiation oncology, biology, physics.
[37] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[38] B. Campbell. The Role of Radiation Therapy in the Treatment of Stage I-II Diffuse Large B-Cell Lymphoma , 2013, Current Hematologic Malignancy Reports.
[39] A. Zelenetz,et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.
[40] W. Wilson,et al. Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype , 2014, Clinical Cancer Research.
[41] G. Altavilla,et al. Should the use of surveillance imaging in diffuse large B-cell lymphoma be discontinued? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Cerhan,et al. Reply to V. Pitini et al and L.J. Costa. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.